SCHEMBL1615697

SCHEMBL1615697

CC(C)c1ccc2c(c1)CCN2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.53
DRD4 P21917 1/20 0.53
ALDH1A1 P00352 3/20 0.45
ATM Q13315 1/20 0.45
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
TSHR P16473 1/20 0.44
GFER P55789 2/20 0.40
KIF11 P52732 1/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421470 0.89 MAPT (0.50) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL18792439 0.85 DRD2 (0.50) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL22864623 0.85 DRD2 (0.53) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL2736868 0.85 GFER (0.50) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL24477467 0.82 DRD2 (0.47) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL7260940 0.80 DRD2 (0.49) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL15341645 0.78 GAA (0.44) ALDH1A1MAPTGAAGFERKIF11
SCHEMBL7570962 0.77 ALDH1A1 (0.51) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL5779828 0.76 ALDH1A1 (0.47) DRD2DRD4ALDH1A1ATMMAPT
SCHEMBL5779829 0.76 ALDH1A1 (0.47) DRD2DRD4ALDH1A1ATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-11-30 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ENLIVEN INC. (US) 2023-11-07 US disclosed
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ENLIVEN INC. (US) 2023-09-26 US disclosed
US-20230296514-A1 Zinc-Selective Fluorescent Probes for Emission-Ratiometric Imaging GEORGIA TECH RESEARCH CORPORATION 2023-09-21 US disclosed
US-11702409-B2 Pyrazolyl derivatives useful as anti-cancer agents NOVARTIS AG (CH) 2023-07-18 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 US disclosed
US-20070066610-A1 Acylhydrazones as kinase modulators JANSSEN PHARMACEUTICAL, N.V. (BE) 2007-03-22 US disclosed
US-20070066610-A1 Acylhydrazones as kinase modulators JANSSEN PHARMACEUTICAL, N.V. (BE) 2007-03-22 US disclosed
EP-1757591-A1 CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-02-28 EP disclosed
US-20070021386-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents TRANSTECH PHARMA (US) 2007-01-25 US disclosed
US-20050171148-A1 Aryl and heteroaryl compounds, compositions, methods of use TRANSTECH PHARMA, LLC 2005-08-04 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
US-5834494-A SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME SMITHKLINE BEECHAM P.L.C. (GB) 1998-11-10 US disclosed
EP-0707581-B1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-02-26 EP disclosed
EP-0707581-A1 INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-04-24 EP disclosed
WO-1995001976-A1 INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702409-B2 Pyrazolyl derivatives useful as anti-cancer agents PAK5, CYP51A1, SF3B5 DRD2 4467/4885DRD4 3704/4885ALDH1A1 901/4885
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A DRD2 3458/4885DRD4 2075/4885ALDH1A1 983/4885
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ABL1, ABL2, BCR DRD2 3917/4885DRD4 4179/4885ALDH1A1 1397/4885
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 DRD2 3992/4885DRD4 4181/4885ALDH1A1 2569/4885
US-20070066610-A1 Acylhydrazones as kinase modulators MET, ERBB2, ERBB3 DRD2 4127/4885DRD4 4277/4885ALDH1A1 379/4885
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR DRD2 3917/4885DRD4 4179/4885ALDH1A1 1397/4885
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 DRD2 108/4885DRD4 384/4885ALDH1A1 591/4885
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ABL1, ABL2, BCR DRD2 3917/4885DRD4 4179/4885ALDH1A1 1397/4885
US-20230296514-A1 Zinc-Selective Fluorescent Probes for Emission-Ratiometric Imaging ZRANB2, ZFR, SLC30A6 DRD2 3803/4885DRD4 3944/4885ALDH1A1 1651/4885
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF DRD2 4318/4885DRD4 4706/4885ALDH1A1 2317/4885
US-20070021386-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B DRD2 4691/4885DRD4 4416/4885ALDH1A1 3093/4885
US-20050171148-A1 Aryl and heteroaryl compounds, compositions, methods of use TFPI, F3, F2 DRD2 2774/4885DRD4 3725/4885ALDH1A1 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.